Interleukin 4 is localized to and released by human mast cells by unknown
Interleukin 4 Is Localized to and Released by Human
Mast Cells
By P . Bradding, I . H . Feather, P. H . Howarth, R . Mueller,*
J. A . Roberts, K . Britten, J . P. A . Bews,* T C . Hunt,
Y Okayama, C . H . Heusser,* G . R . Bullock,* M . K . Church,
and S . T Holgate
From the Immunopharmacology Group, Medicine I, Southampton General Hospital,
Southampton, S09 4XY United Kingdom; and *Ciba-Geigy, Basel, Switzerland
Summary
Recent attention has focused on theT helper type 2 (Th2) lymphocyte as a source of interleukin
4 (IL4) in allergic disease . However, Th2 cells themselves require a pulse of IL-4 to initiate this
synthesis. Here we provide immunohistochemical evidence of IL-4 localization to human mast
cells of the skin and respiratory tract, and demonstrate that immunoglobulin E-dependent
stimulation of purified human lung mast cells leads to the rapid release of IL-4 into the extracellular
environment . We propose that mast cell activation in an allergic response provides a rapid and
local pulse of IL-4 into the local environment essential for the triggering of T lymphocytes into
sustained IL-4 production and to initiate inflammatory cell accumulation and activation.
L4 is a multifunctional cytokine that appears to play an
important role in the pathogenesis of allergic disease . In
particular, the isotype switching ofB cells to IgE synthesis
is under the control of IL-4 (1), and in vivo IgE responses
in mice are inhibited after prior administration of neutralizing
IL-4 antibodies (2) . IL-4-deficient mice, which cannot pro-
duce IL-4, do not develop IgE responses (3), whereas trans-
genic mice with enhanced IL-4 production develop high cir-
culating IgE levels, and a severe chronic conjunctivitis,
characterized by mononuclear, mast cell, and eosinophil
infiltration (4) . These cellular changes are similar to those
observed in human allergic asthma, rhinitis, dermatitis, and
keratoconjunctivitis . In atopic human subjects increased
numbers of cells positive for IL-4 mRNA have been found
to be present during the allergen-induced late-phase cutaneous
response, suggesting IL-4 is upregulated in human allergic
disease (5) . Both human and rodent T cells of theTh2 pheno-
type have been shown to produce this cytokine, but they first
require the presence of IL-4 for their own development (6,
7) . It is our hypothesis that in an allergic response this signal
may come from the mast cell . In support ofthis, IL-4 genera-
tion has also been shown by rodent mast cells (8) and by
rodent (9) and human (10) non-B non-T cells, which have
mast cell basophil characteristics. We have used immuno-
histochemistry to study the presence and cellular localization
of IL4 in situ in the human respiratory tract, validated the
method in IL4 gene-transfected hamster CHO cells, sup-
plemented our findings by immunostaining ofpurified human
skin and lung mast cells for IL4, and demonstrated its re-
lease along with histamine from mast cells with IgE-dependent
activation .
Materials and Methods
Human Subjects andBiopsySpecimens.
￿
Nasal biopsies were taken
from the inferior or inferomedial edge of the inferior turbinate of
four patients with allergic perennial rhinitis using 2-mm cupped
Hartman's forceps (Medicom, Tuttlingen, Germany) under tetra-
caine local anesthesia . Bronchial biopsies were taken from the right
middle lobe carina in four perennial allergic asthmatic patients via
a fiber-optic bronchoscope (BFIT20; Olympus Company, Tokyo,
Japan) using alligator forceps (Olympus FB15E) (11) . All patients
gave written informed consent and the biopsy procedures were ap-
provedby the Southampton University and Hospitals Ethical Com-
mittee. In each instance the biopsy specimens were fixed in ice-
cooled acetone containing the protease inhibitors iodoacetamide
and PMSF, then stored for 24 h at -20°C before processing into
glycol methacrylate (GMA) . Biopsies were placed in acetone, then
methylbenzoate for 15 min each at room temperature, transferred
to GMA JB4 solution (Polysciences, Northampton, UK) at 4°C,
followed by embedding in GMA resin .
Immunohistochemistry o .f Biopsy Specimens .
￿
For immunohisto-
chemistry, 2-/Am sections were cut by ultramicrotomy, floated on
0.2% ammonia solution in water for 1 min, and dried at room
temperature for 1-4 h . Sections were pretreated with 10 ml 0.1%
sodium azide solution containing 100 Al 30% hydrogen peroxide
for 30 min to inhibit endogenous peroxidase . Mouse IgG1 mAbs
384 and 4139 to human 11,4 (12), AA1 to mast cell tryptase, anti-
CD3, and anti-CD4 were applied to sequential sections. A bio-
tinylated rabbit anti-mouse (Dako Ltd ., High Wycombe, UK)
second stage was applied and subsequently demonstrated using the
streptavidin-biotin peroxidase complex detection system . Amino-
ethylcarbazole (AEC) was used as chromogen giving a red reac-
tion product, and sections were counterstained in Mayers hema-
toxylin . Control slides were similarly treated, either with the pri-
mary antibody omitted, or in the presence of an unrelated mouse
IgG1 mAb at the same concentration as the anti-IL4 antibodies .
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the first antibody as describedusingthe streptavidin-biotin peroxi-
dase detectionsystem. This process was then repeated forthesecond
antibodybutby utilizing the streptavidin-biotin alkaline phospha-
tase detection system (Dako Ltd.) using fast blue B.B as the chro-
mogen. No counterstain was applied. Controls were performed
with no antibody, either theanti-tryptase, anti-CD3, or anti-IL-4
antibody absent, andwith each antibody applied first, to show that
the detection system for the second antibody did not crossreact
with the first antibody.
Mast Cell Purification.
￿
Foreskin mast cells were dispersed from
circumcision specimensusingcollagenase (1.5 mg/ml) andhyaluroni-
dase (0.75 mg/ml) as previously described (13). The isolated cells
were layered onto adiscontinuousgradient of60-80% Percoll (den-
sity, 1.076-1.1 g/ml) andcentrifuged at 500g for 20 min at 4°C.
Mast cells at thebottom of thegradient andbetween the70/80%
interface were 90% pure. T lymphocytes were removedby incuba-
tion of resuspended cells for 30 min at 4°C with magnetic beads
coated with a mAb specific for the CD2 T cell antigen (Dynal,
Oslo, Norway). Two 15-min exposuresto a magnet removed 99%
of CD2-positive T cells.Lung mast cells were dispersed from mac-
roscopically normal human lung, obtained within 1 h of resection
as described for the skin above. Due to thedifferent nature ofcon-
taminating cellsin thedispersate, it was notpossible to usedensity
sedimentation alone to purify lung mast cells. Erythrocytes were
removedby centrifugation througha 65% continuous Percollgra-
dient (1.084 g/ml), and the nucleated cells were incubated for 30
min with 5 jig/ml of the mAb YB5.B8 (kindly donated by L.
Ashman, Melbourne, Australia), which recognizes the mast cell
c-kit receptor. Cells were then washed and incubated for 60 min
with a 500-IAI suspension of magnetic beads coated with goat
anti-mouse IgG antibody (Dynal)at 4°C on a roller. Purified mast
cells attached to magnetic beads were removed from the suspen-
sion with a magnet.
Immunohistochemistry ofPurified Mast Cells.
￿
For immunocyto-
chemical staining, purified mast cells were fixed in buffered 4%
paraformaldehyde (20 min), and cytospin preparations were made.
The mast cells were then stained for IL4 with three mAbs, 3H4,
4D9, and 8F12 (12), using the alkaline phosphatase anti-alkaline
phosphatase (APAAP) detection system with fast red as the chro-
mogen for skin cells and fast blue as the chromogen for the lung
cells to help distinguish cells from dynabeads. Negative controls
were performed with primary antibody absent and an unrelated
mouse IgG1 mAb. Specificity of immunostaining was demonstrated
in Chinese hamsterovary(CHO) cells transfected with cDNA for
humanIL-4. IL4 immunoreactivity wasshownwith themAb3H4,
whichcouldbe effectively inhibitedwhen the3114 mAbwasprein-
cubated with rhIL4 (Fig. 1) . Positive immunostaining of IL4-
transfected CHO cells was also observed with the anti-IL-4 mAbs
4D9 and 8F12.
IL4 Release by Purified Mast Cells.
￿
After purification mast cells
were resuspended in cold HBSS' and allowed to warm slowly to
room temperature. Aliquots ofthe cell suspension were made (225
I.I containing N5-10 x 10° mast cells/tube) and preincubated for
15 min before addition of 25 P1 of 10x concentrated anti-IgE or
HBSS' (control). Cells were then incubated for 1, 2, 4, or 6 h,
and thereleasereaction was stopped by centrifugation (5 min, 500
g, 4°C) . Supernatants were decanted and frozen at -80°C. For
histamine analysis, TCA was added to afinalconcentration of 5%
before freezing. Histaminewas measured spectrophotofluorimetri-
callyandIL-4 assayed by ELISA, which hasalower detection limit
of40 pg/mlofIL-4 and acoefficient ofvariationof4% in therange
of 60-2,000 pg/ml.
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Results and Discussion
In all the biopsies from both the rhinitic and asthmatic
subjects, cells staining positively for IL4 were present (Fig.
2). No significant immunostaining was identified in either
the absence of antibody or in the presence of an unrelated
antibody control. On identifying the same nucleated, IL4-
immunoreactive cell in adjacent 2-um sections, positive
staining was seen with both the 3114 and4139 mAbs, which
recognizedifferent epitopes on human IL4, therebyconfirming
the identity of immunoreactivity as IL-4. When immuno-
staining with AA1, an antibody against mast cell tryptase,
was also performed in adjacent sections (Fig. 2), or in the
same section (Fig. 3), IL-4 immunoreactivity was found to
be localized to mast cells. Comparison of sequential sections
stained in the eight biopsies using the camera-lucida system
(Leica UK Limited, Milton Keynes, UK) has shownthat the
percentage ofIL-4-containingcells that were also tryptase posi-
tive ranged from 78 to 100%, while the number of tryptase-
positive cells that were also IL-4 positive ranged from 68 to
85%. No IL-4 immunoreactivity waslocalizedto either CD3-
or C134-positive T cells with either double staining or com-
parison of sequential sections. No crossreactionwas observed
in the double-stained controls.
Investigation of IL-4 immunoreactivity using the anti-
human IL-4 antibodies 3H4, 4D9, and 8F12 in mast cells,
dispersed from both humanlung and skin purified to >95%,
confirmed the intracellularlocalization ofIL-4 (Fig. 4) . Anti-
IgEchallenge resulted in specific release of IL4 from purified
human lung mast cells (n = 3), with mean levels in cells
challenged with anti-IgE and unchallenged controls of 13.2
ng/106 cells and <0.5 ng/106 cells, respectively (Fig. 5).
Theimmunocytochemical andELISA techniques we have
used, chosen in preference to estimation ofmRNA by in situ
hybridization, whichdoes not always reflect protein synthesis
and cannot detect storage, have clearly demonstrated that
human mast cells contain and release IL-4. The studies with
biopsies and isolated cells have allowed us to examine mast
cells from several tissue sites, all of which show IL-4 im-
munoreactivity with three different mAbs. This observation
strongly suggests that the presence of IL-4 is not restricted
to one mast cell subset, the mast cells of the skin and lung
being phenotypically distinct (14) . Thus, mast cells at both
connective tissue and mucosal sites may participate in allergic
inflammation through IL-4 release. In experiments to assess
IL-4 release from lung mast cells, we have used an ELISA
to quantitate IL-4 after anti-IgE challenge. The observation
that anti-IgE released similar amounts of IL-4 at 1, 2, 4, and
6 h suggests that this cytokine seems to be present within
the cells in a preformed state similar to that reported for
TNF-cx (15).
Thespecificity of our immunostaining for IL4is suggested
by several factors. First, in the tissue section, the two specific
IL-4 antibodies used, 3114 and 4D9, stain the same cells in
spiteofreacting with different epitopes on humanIL4, while
an isotype control antibody at the same Ig concentrationwas
negative. Second, with the purified cells, the threeantibodies
used, 3114, 4139, and8F12, all give positive staining, whereasFigure 1 .
￿
Cytocentrifuged IIr4-transfected (CHO) cells (top) and non-
transfected CHO cells (middle) showing positive and negative staining,
respectively, withmAb 3114 . Incubation ofmAb 3114 with an excess of
IL4 before staining oftransfected cells greatly reduced IIT4 immunostaining
(bottom) .
an isotype control was again negative. Third,CHO cells trans-
fected with the human IL4 gene and known to secrete large
quantities ofIL4 stained positively with the IL4 antibodies,
whereas CHO cells without gene transfection were nega-
tive . Incubation of antibodies with IL4 before staining greatly
reduced staining of IL4-positive CHO cells but was unhelpful
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Figure 2 .
￿
Immunohistological staining with antibodies 3114 against
human IL4 (top), AAI against mast cell tryptase (middle), and 4D9 also
against human IL4 (bottom) in sequential 2-pm sections of a mucosal bi-
opsy from a patient with atopic asthma showing cellular staining with
both anti-114 antibodies and the anti-mast cell tryptase antibody.
in tissue sections due to marked subsequent background
staining, probably due to nonspecific binding ofimmune com-
plexes to resin sections, or binding ofimmune complexes via
the IL-4 receptor, as neither antibodies employed in the tissue
sections were neutralizing.
These findings have considerable relevance to the patho-
genesis of chronic allergic inflammation and in particular for
the role of the tissue mast cell in its initiation . IL-4 has many
effects that promote allergic inflammation . These include :Figure 3 .
￿
Double immunostaining of 2-Am sections from a nasal bi-
opsywith antibody AAl against mast cell tryptase and 3H4 against human
IL4 (top), and a bronchial biopsy withAAl and 4D9 also against human
IL4 (bottom) identifying the localization of 114 immunoreactivity tomast
cells .
upregulation of IgE synthesis (1) ; stimulation ofT cell prolifer-
ation and Th2 cell development (6, 7, 16) ; induction ofMHC
class II molecules on B cells and monocytes (17, 18) ; induc-
tion ofF,ER (CD23) on B cells and macrophages (17, 19) ;
induction of LFA-1 and LFA-3 on B cells (20) ; activation of
macrophages (21) ; proliferation of fibroblasts (22) ; induction
ofVCAM-1 on endothelial cells (23) ; increased mast cell basal
and stimulated histamine release (24) ; the promotion of eo-
sinophil and mast cell accumulation at the site of allergic reac-
tions (25, 26) ; and mast cell growth and maturation (27) .
The source of IL-4 necessary to maintain these responses
is considered to be the T lymphocyte, particularly its Th2
subset (28) . However the Th2 lymphocyte itself requires IL-4
to initiate and support its development and cytokine synthesis
(6, 7) . It is our hypothesis that the release of IL-4 from the
mast cell after IgE-dependent activation provides a localized
initiating stimulus for the activation of Th2 cells. Further-
more, we suggest that mast cell cytokine release within minutes
ofallergen provocation plays a major role in the early accumu-
1384
￿
Human Mast Cells Release IL4
Figure 4.
￿
IL4 immunostaining of human mast cells dispersed andpurified
from resected foreskin stained with the 3H4 and anti-human IL4 antibody .
Figure 5 .
￿
Levels of histamine (expressed as )Ag/10 6 mast cells ; top) and
ILA (ng/106 cells ; bottom) in culture supernatants from purified lung mast
cells after either saline control (open ban) or anti-IgE challenge (striped ban) .
lation of inflammatory cells observed . Thus, in addition to
being the source of histamine and eicosanoids, which are
responsible for most of the symptoms of the early phase of
an allergic response, mast cells may play an obligatory role
in the initiation, and possibly the maintenance, of allergic
inflammation through the production and release of IL4,
TNF-a, and possibly other cytokines.References
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